In vivo effects of the anti-interleukin-6 receptor inhibitor tocilizumab on the B cell compartment

Arthritis and Rheumatism

Volumn 63, Issue 5, 2011, Pages 1255-1264

  Roll, Petra ^a   Muhammad, Khalid ^a   Schumann, Mathias ^a   Kleinert, Stefan ^a   Einsele, Hermann ^a   Dörner, Thomas ^b   Tony, Hans Peter ^a,c  

^a UNIVERSITY OF WÜRZBURG   (Germany)

^b CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^c UNIVERSITY HOSPITAL WÜRZBURG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

CD19 ANTIGEN; IMMUNOGLOBULIN A; IMMUNOGLOBULIN G; INTERLEUKIN 6; TOCILIZUMAB;

ADULT; AGED; ARTICLE; B LYMPHOCYTE; B LYMPHOCYTE DIFFERENTIATION; CLINICAL ARTICLE; CONTROLLED CLINICAL TRIAL; DRUG EFFECT; FEMALE; GENE REARRANGEMENT; HUMAN; IMMUNOGLOBULIN BLOOD LEVEL; IMMUNOPHENOTYPING; IN VIVO STUDY; MALE; MEMORY CELL; PRIORITY JOURNAL; RHEUMATOID ARTHRITIS;

ADULT; AGED; ANTIBODIES, MONOCLONAL; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; B-LYMPHOCYTES; CELL COUNT; FEMALE; FLOW CYTOMETRY; HUMANS; IMMUNOPHENOTYPING; MALE; MIDDLE AGED; RECEPTORS, INTERLEUKIN-6;

EID: 79955569760     PISSN: 00043591     EISSN: 15290131     Source Type: Journal    
DOI: 10.1002/art.30242     Document Type: Article

References (40)

1. Fonseca JE, Santos MJ, Canhao H, Choy E,. Interleukin-6 as a key player in systemic inflammation and joint destruction. Autoimmun Rev 2009; 8: 538-42.
2. Lipsky PE,. Interleukin-6 and rheumatic diseases. Arthritis Res Ther 2006; 8 Suppl 2: S4.
3. Nishimoto N, Terao K, Mima T, Nakahara H, Takagi N, Kakehi T,. Mechanisms and pathologic significances in increase in serum interleukin-6 (IL-6) and soluble IL-6 receptor after administration of an anti-IL-6 receptor antibody, tocilizumab, in patients with rheumatoid arthritis and Castleman disease. Blood 2008; 112: 3959-64.
4. Rose-John S, Scheller J, Elson G, Jones SA,. Interleukin-6 biology is coordinated by membrane-bound and soluble receptors: role in inflammation and cancer. J Leukoc Biol 2006; 80: 227-36. (Pubitemid 44835496)
5. Muraguchi A, Hirano T, Tang B, Matsuda T, Horii Y, Nakajima K, et al. The essential role of B cell stimulatory factor 2 (BSF-2/IL-6) for the terminal differentiation of B cells. J Exp Med 1988; 167: 332-44. (Pubitemid 18073639)
6. Jones SA,. Directing transition from innate to acquired immunity: defining a role for IL-6. J Immunol 2005; 175: 3463-8. (Pubitemid 41292002)
7. Wu Y, El Shikh ME, El Sayed RM, Best AM, Szakal AK, Tew JG,. IL-6 produced by immune complex-activated follicular dendritic cells promotes germinal center reactions, IgG responses and somatic hypermutation. Int Immunol 2009; 21: 745-56.
8. Kopf M, Herren S, Wiles MV, Pepys MB, Kosco-Vilbois MH,. Interleukin 6 influences germinal center development and antibody production via a contribution of C3 complement component. J Exp Med 1998; 188: 1895-906. (Pubitemid 28536777)
9. + T cells. J Exp Med 2009; 206: 69-78.
10. Silverman GJ, Carson DA,. Roles of B cells in rheumatoid arthritis. Arthritis Res Ther 2003; 5 Suppl 4: S1-6. (Pubitemid 38239909)
11. Madhok R, Crilly A, Watson J, Capell HA,. Serum interleukin 6 levels in rheumatoid arthritis: correlations with clinical and laboratory indices of disease activity. Ann Rheum Dis 1993; 52: 232-4. (Pubitemid 23094315)
12. Houssiau FA, Devogelaer JP, Van Damme J, de Deuxchaisnes CN, Van Snick J,. Interleukin-6 in synovial fluid and serum of patients with rheumatoid arthritis and other inflammatory arthritides. Arthritis Rheum 1988; 31: 784-8.
13. Kotake S, Sato K, Kim KJ, Takahashi N, Udagawa N, Nakamura I, et al. Interleukin-6 and soluble interleukin-6 receptors in the synovial fluids from rheumatoid arthritis patients are responsible for osteoclast-like cell formation. J Bone Miner Res 1996; 11: 88-95. (Pubitemid 26026748)
14. Silverman GJ, Boyle DL,. Understanding the mechanistic basis in rheumatoid arthritis for clinical response to anti-CD20 therapy: the B-cell roadblock hypothesis. Immunol Rev 2008; 223: 175-85. (Pubitemid 351986172)
15. Dayer JM, Choy E,. Therapeutic targets in rheumatoid arthritis: the interleukin-6 receptor. Rheumatology (Oxford); 49: 15-24.
16. Ballara S, Taylor PC, Reusch P, Marme D, Feldmann M, Maini RN, et al. Raised serum vascular endothelial growth factor levels are associated with destructive change in inflammatory arthritis. Arthritis Rheum 2001; 44: 2055-64. (Pubitemid 33644048)
17. Emery P, Keystone E, Tony HP, Cantagrel A, van Vollenhoven R, Sanchez A, et al. IL-6 receptor inhibition with tocilizumab improves treatment outcomes in patients with rheumatoid arthritis refractory to anti-tumour necrosis factor biologicals: results from a 24-week multicentre randomised placebo-controlled trial [published erratum appears in Ann Rheum Dis 2009;68:296]. Ann Rheum Dis 2008; 67: 1516-23.
18. Genovese MC, McKay JD, Nasonov EL, Mysler EF, da Silva NA, Alecock E, et al. Interleukin-6 receptor inhibition with tocilizumab reduces disease activity in rheumatoid arthritis with inadequate response to disease-modifying antirheumatic drugs: the Tocilizumab in Combination With Traditional Disease-Modifying Antirheumatic Drug Therapy study. Arthritis Rheum 2008; 58: 2968-80.
19. Arnett FC, Edworthy SM, Bloch DA, McShane DJ, Fries JF, Cooper NS, et al. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 1988; 31: 315-24. (Pubitemid 18091653)
20. Prevoo ML, van 't Hof MA, Kuper HH, van Leeuwen MA, van de Putte LB, van Riel PL,. Modified disease activity scores that include twenty-eight-joint counts: development and validation in a prospective longitudinal study of patients with rheumatoid arthritis. Arthritis Rheum 1995; 38: 44-8.
21. Van Gestel AM, Prevoo ML, van 't Hof MA, van Rijswijk MH, van de Putte LB, van Riel PL,. Development and validation of the European League Against Rheumatism response criteria for rheumatoid arthritis: comparison with the preliminary American College of Rheumatology and the World Health Organization/International League Against Rheumatism criteria. Arthritis Rheum 1996; 39: 34-40. (Pubitemid 26036375)
22. Cassese G, Arce S, Hauser AE, Lehnert K, Moewes B, Mostarac M, et al. Plasma cell survival is mediated by synergistic effects of cytokines and adhesion-dependent signals. J Immunol 2003; 171: 1684-90. (Pubitemid 36966450)
23. Manz RA, Arce S, Cassese G, Hauser AE, Hiepe F, Radbruch A,. Humoral immunity and long-lived plasma cells. Curr Opin Immunol 2002; 14: 517-21. (Pubitemid 34671256)
24. Garnero P, Thompson E, Woodworth T, Smolen JS,. Rapid and sustained improvement in bone and cartilage turnover markers with the anti-interleukin-6 receptor inhibitor tocilizumab plus methotrexate in rheumatoid arthritis patients with an inadequate response to methotrexate: results from a substudy of the multicenter double-blind, placebo-controlled trial of tocilizumab in inadequate responders to methotrexate alone. Arthritis Rheum 2010; 62: 33-43.
25. Nishimoto N, Kanakura Y, Aozasa K, Johkoh T, Nakamura M, Nakano S, et al. Humanized anti-interleukin-6 receptor antibody treatment of multicentric Castleman disease. Blood 2005; 106: 2627-32. (Pubitemid 41510733)
26. Ito H, Takazoe M, Fukuda Y, Hibi T, Kusugami K, Andoh A, et al. A pilot randomized trial of a human anti-interleukin-6 receptor monoclonal antibody in active Crohn's disease. Gastroenterology 2004; 126: 989-96. (Pubitemid 38451170)
27. Tackey E, Lipsky PE, Illei GG,. Rationale for interleukin-6 blockade in systemic lupus erythematosus. Lupus 2004; 13: 339-43. (Pubitemid 38788493)
28. Henneken M, Dorner T, Burmester GR, Berek C,. Differential expression of chemokine receptors on peripheral blood B cells from patients with rheumatoid arthritis and systemic lupus erythematosus. Arthritis Res Ther 2005; 7: R1001-13.
29. Fekete A, Soos L, Szekanecz Z, Szabo Z, Szodoray P, Barath S, et al. Disturbances in B- and T-cell homeostasis in rheumatoid arthritis: suggested relationships with antigen-driven immune responses. J Autoimmun 2007; 29: 154-63. (Pubitemid 47385116)
30. Jacobi AM, Dorner T,. Current aspects of anti-CD20 therapy in rheumatoid arthritis. Curr Opin Pharmacol 2010; 10: 316-21.
31. Souto-Carneiro MM, Mahadevan V, Takada K, Fritsch-Stork R, Nanki T, Brown M, et al. Alterations in peripheral blood memory B cells in patients with active rheumatoid arthritis are dependent on the action of tumour necrosis factor. Arthritis Res Ther 2009; 11: R84.
32. Moura RA, Weinmann P, Pereira PA, Caetano-Lopes J, Canhao H, Sousa E, et al. Alterations on peripheral blood B-cell subpopulations in very early arthritis patients. Rheumatology (Oxford) 2010; 49: 1082-92.
33. Leandro MJ,. Anti-tumour necrosis factor therapy and B cells in rheumatoid arthritis. Arthritis Res Ther 2009; 11: 128.
34. Martinez-Gamboa L, Mei H, Loddenkemper C, Ballmer B, Hansen A, Lipsky PE, et al. Role of the spleen in peripheral memory B-cell homeostasis in patients with autoimmune thrombocytopenia purpura. Clin Immunol 2009; 130: 199-212.
35. Kruetzmann S, Rosado MM, Weber H, Germing U, Tournilhac O, Peter HH, et al. Human immunoglobulin M memory B cells controlling Streptococcus pneumoniae infections are generated in the spleen. J Exp Med 2003; 197: 939-45. (Pubitemid 36437871)
36. Roll P, Dorner T, Tony HP,. Anti-CD20 therapy in patients with rheumatoid arthritis: predictors of response and B cell subset regeneration after repeated treatment. Arthritis Rheum 2008; 58: 1566-75. (Pubitemid 351847509)
37. Odendahl M, Jacobi A, Hansen A, Feist E, Hiepe F, Burmester GR, et al. Disturbed peripheral B lymphocyte homeostasis in systemic lupus erythematosus. J Immunol 2000; 165: 5970-9.
38. Illei GG, Shirota Y, Yarboro CH, Daruwalla J, Tackey E, Takada K, et al. Tocilizumab in systemic lupus erythematosus: data on safety, preliminary efficacy, and impact on circulating plasma cells from an open-label phase I dosage-escalation study. Arthritis Rheum 2010; 62: 542-52.
39. Klashman DJ, Martin RA, Martinez-Maza O, Stevens RH,. In vitro regulation of B cell differentiation by interleukin-6 and soluble CD23 in systemic lupus erythematosus B cell subpopulations and antigen-induced normal B cells. Arthritis Rheum 1991; 34: 276-86.
40. Ramsay AJ, Husband AJ, Ramshaw IA, Bao S, Matthaei KI, Koehler G, et al. The role of interleukin-6 in mucosal IgA antibody responses in vivo. Science 1994; 264: 561-3. (Pubitemid 24185859)